Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,070 GBX | -4.46% | +3.38% | +57.35% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Sales 2023 * | 500K 625K | Sales 2024 * | 2M 2.5M | Capitalization | 137M 171M |
---|---|---|---|---|---|
Net income 2023 * | -7M -8.74M | Net income 2024 * | -7M -8.74M | EV / Sales 2023 * | 260 x |
Net cash position 2023 * | 7.2M 8.99M | Net cash position 2024 * | 15.1M 18.86M | EV / Sales 2024 * | 61 x |
P/E ratio 2023 * |
-17.8
x | P/E ratio 2024 * |
-17.8
x | Employees | 78 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 30.4% |
1 day | -4.46% | ||
1 week | +3.38% | ||
Current month | +11.46% | ||
1 month | +12.63% | ||
3 months | +62.12% | ||
6 months | +114.00% | ||
Current year | +57.35% |
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1,070 | -4.46% | 2,239 |
24-04-25 | 1,120 | +4.67% | 849 |
24-04-24 | 1,070 | +2.39% | 3,229 |
24-04-23 | 1,045 | 0.00% | 96 |
24-04-22 | 1,045 | +0.97% | 1,418 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+57.35% | 179M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- 4BB Stock